ABIOMED (ABMD) Shares are Up 1.48%

ABIOMED (ABMD) : Traders are bullish on ABIOMED (ABMD) as it has outperformed the S&P 500 by a wide margin of 3.6% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.55%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.48% in the last 1 week, and is up 7.08% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 2.63% and the 50-Day Moving Average is 10.59%. ABIOMED, Inc. is up 21.44% in the last 3-month period. Year-to-Date the stock performance stands at 30.67%.


ABIOMED (NASDAQ:ABMD): stock turned positive on Friday. Though the stock opened at $115.24, the bulls momentum made the stock top out at $119.93 level for the day. The stock recorded a low of $115.24 and closed the trading day at $117.97, in the green by 2.56%. The total traded volume for the day was 880,073. The stock had closed at $115.03 in the previous days trading.

Abiomed, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Companys products include Impella 2.5, a percutaneous micro heart pump with an integrated motor and sensors; Impella CP, which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD, a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000, a circulatory support system for the temporary support of acute heart failure patients in profound shock, and Symphony, a minimally invasive implantable cardiac assist device.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.